Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|December 4, 1996

SMV pursues high-energy imaging

Like many other nuclear medicine vendors, SMV of Twinsburg, OH,is developing high-energy imaging technologies to image fluorodeoxyglucose,the radiotracer used in most PET studies. At its RSNA booth, SMVwill display both collimated and coincidence

Like many other nuclear medicine vendors, SMV of Twinsburg, OH,is developing high-energy imaging technologies to image fluorodeoxyglucose,the radiotracer used in most PET studies. At its RSNA booth, SMVwill display both collimated and coincidence detection-based high-energymethods, according to Robert Ripley, director of corporate communications.

SMV will also debut a new motion-correction program designedto work with its Transmission Attenuation Correction (TAC) productand its Restore resolution recovery algorithm.


Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.